Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding
Authors:
- 1 March 2022
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 47 (4) , 1464-1472
Abstract
Background and Aim An increasing number of patients with autoimmune hepatitis (AIH)-induced cirrhosis and variceal bleeding are currently referred for transjugular intrahepatic portosystemic shunt (TIPS). The aim of this study was to evaluate the safety and efficacy of TIPS in such patients, and to compare these results with data from patients with hepatitis B virus (HBV)-induced cirrhosis. Materials and Methods This retrospective study consisted of 211 patients between August 2016 and May 2021, and patients were allocated to AIH (n = 35) and HBV (n = 176) groups according to the etiology of the cirrhosis. The primary endpoint was mortality after TIPS use; the secondary endpoints were recurrent bleeding, overt hepatic encephalopathy (OHE), shunt dysfunction, and dynamic changes in liver function over time. Results During a median follow-up period of 27 months, 23 (10.9%) patients died, 22 (10.4%) experienced recurrent bleeding, 50 (23.7%) experienced OHE, and 25 (11.8%) developed shunt dysfunction. Compared with the HBV group, the AIH group exhibited a similar mortality risk (adjusted hazard ratio, HR 1.199; 95% confidence interval, CI 0.367–3.917; p = 0.764), OHE (adjusted HR 1.023, 95% CI 0.483–2.167, p = 0.954), and shunt dysfunction (adjusted HR 0.862, 95% CI 0.285–2.610, p = 0.792); but a higher risk of recurrent bleeding (adjusted HR 2.731, 95% CI 1.112–6.708, p = 0.028). The dynamic changes in liver function manifested an initial trend toward deterioration, and then subsequent recovery in both the AIH and HBV groups. Conclusions TIPS is a safe and effective treatment, and should be considered for those patients with AIH-induced cirrhosis and variceal bleeding. Graphical abstractKeywords
Funding Information
- Medical Science and Technology Project of Henan Province (LHGJ20190562)
- National Natural Science Foundation of China (81873917)
This publication has 28 references indexed in Scilit:
- Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic FactorsRadiology, 2016
- Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β‐blocker for prevention of variceal rebleedingHepatology, 2015
- Autoimmune hepatitis – Update 2015Journal of Hepatology, 2015
- Autoimmune hepatitis: East meets westJournal of Gastroenterology and Hepatology, 2015
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverHepatology, 2014
- Autoimmune Hepatitis, Cirrhosis, and Hepatocellular Carcinoma (HCC)Digestive Diseases and Sciences, 2010
- Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene‐covered stents versus bare stents: A meta‐analysisJournal of Gastroenterology and Hepatology, 2010
- Stent-grafts for Transjugular Intrahepatic Portosystemic Shunt Creation: Specialized TIPS Stent-graft versus Generic Stent-graft/Bare Stent CombinationJournal of Vascular and Interventional Radiology, 2010
- Early Use of TIPS in Patients with Cirrhosis and Variceal BleedingNew England Journal of Medicine, 2010
- Hepatic arterial buffer response in patients with advanced cirrhosisHepatology, 2002